2541. The Rationale for Strategy Trials in Infectious Diseases
Session: Symposium: Strategy Trials: A New Paradigm in Infectious Diseases Research
Saturday, October 6, 2018: 2:00 PM
Room: W 2005-2024
Vance G. Fowler Jr., MD, Duke University Medical Center, Durham, NC


Disclosures:

V. G. Fowler Jr., Cerexa/Actavis/Allergan, Pfizer, Advanced Liquid Logics, NIH, MedImmune, Basilea Pharmaceutica, Karius, ContraFect, Regeneron Pharmaceuticals, and Genentech: Grant Investigator , Grant recipient . Achaogen, Astellas Pharma, Arsanis, Affinergy, AmpliPhi, Basilea Pharmaceutica, Bayer, Cerexa Inc., ContraFect, Cubist, Debiopharm, Durata Therapeutics, Grifols, Genentech, MedImmune, Merck, The Medicines Company, Pfizer, Novartis, NovaDigm Therapeutics: Consultant , Consulting fee . Theravance Biopharma, Inc., and Green Cross: Lecturer , Speaker honorarium . UpToDate: Author , Royalties .

Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.